VistaGen Therapeutics Stock (NASDAQ:VTGN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.50

52W Range

$2.22 - $5.86

50D Avg

$2.81

200D Avg

$3.60

Market Cap

$71.56M

Avg Vol (3M)

$231.96K

Beta

0.78

Div Yield

-

VTGN Company Profile


VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

39

IPO Date

Jun 21, 2011

Website

VTGN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 22
License$1.11M

Fiscal year ends in Mar 24 | Currency in USD

VTGN Financial Summary


Mar 24Mar 23Mar 22
Revenue$1.06M$-227.30K$1.11M
Operating Income$-33.02M$-59.19M$-47.78M
Net Income$-29.36M$-59.25M$-47.76M
EBITDA$-33.02M$-58.68M$-46.82M
Basic EPS$-1.52$-8.51$-7.24
Diluted EPS$-1.52$-8.51$-7.24

Fiscal year ends in Mar 24 | Currency in USD

Latest Earnings Call Transcripts


Q2 25Nov 10, 24 | 7:43 AM
Q1 25Aug 13, 24 | 7:05 PM
Q4 24Jun 11, 24 | 6:41 PM

Peer Comparison


TickerCompany
ACIUAC Immune SA
SYBXSynlogic, Inc.
REVBRevelation Biosciences, Inc.
DRMADermata Therapeutics, Inc.
XBIOXenetic Biosciences, Inc.
BPTHBio-Path Holdings, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
CYTOAltamira Therapeutics Ltd.
TPSTTempest Therapeutics, Inc.
ENTXEntera Bio Ltd.
KZRKezar Life Sciences, Inc.
COCPCocrystal Pharma, Inc.